Louise Leong, ABPI Director of Research and Development Policy, welcomes the review of Section 24 of the Animals Act 1986.
“The ABPI welcomes the Home Office consultation on the review of Section 24 of the Animals (Scientific Procedures) Act 1986, and will be giving it due consideration with our member companies. The pharmaceutical industry is committed to greater transparency on the use of animals in research and the ABPI, and many of our members, declared this commitment by signing the Declaration on the Openness in Animal Research. This recognises our duty to be transparent and accountable for the research we conduct, fund and support. The ABPI would be looking for reassurance that any amendments to this Act do not compromise the safety of people who work in animal research and also continues to support the competitiveness of the UK in Life Sciences by ensuring the confidentiality of intellectual property and commercially sensitive information.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
Media enquiriesABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com